BR112021021600A2 - Método para tratamento de tosse usando composto de diaminopirimidina - Google Patents
Método para tratamento de tosse usando composto de diaminopirimidinaInfo
- Publication number
- BR112021021600A2 BR112021021600A2 BR112021021600A BR112021021600A BR112021021600A2 BR 112021021600 A2 BR112021021600 A2 BR 112021021600A2 BR 112021021600 A BR112021021600 A BR 112021021600A BR 112021021600 A BR112021021600 A BR 112021021600A BR 112021021600 A2 BR112021021600 A2 BR 112021021600A2
- Authority
- BR
- Brazil
- Prior art keywords
- cough
- diaminopyrimidine compound
- compound
- treating
- treating cough
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085180 | 2019-04-30 | ||
| PCT/CN2020/087686 WO2020221274A1 (zh) | 2019-04-30 | 2020-04-29 | 二氨基嘧啶类化合物治疗咳嗽的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021600A2 true BR112021021600A2 (pt) | 2022-01-04 |
Family
ID=73029672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021600A BR112021021600A2 (pt) | 2019-04-30 | 2020-04-29 | Método para tratamento de tosse usando composto de diaminopirimidina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220211703A1 (https=) |
| EP (1) | EP3960179B1 (https=) |
| JP (1) | JP7665529B2 (https=) |
| KR (1) | KR102935436B1 (https=) |
| CN (1) | CN114007619B (https=) |
| AU (1) | AU2020265327B2 (https=) |
| BR (1) | BR112021021600A2 (https=) |
| MX (1) | MX2021013338A (https=) |
| SG (1) | SG11202111877TA (https=) |
| TW (1) | TWI736243B (https=) |
| WO (1) | WO2020221274A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1930135B (zh) * | 2004-03-05 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶 |
| CA2619919C (en) * | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| AU2007304280B2 (en) | 2006-10-04 | 2013-01-31 | F. Hoffmann-La Roche Ag | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| RU2650118C2 (ru) * | 2013-08-23 | 2018-04-09 | Афферент Фармасьютикалз Инк. | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться |
| KR20180054843A (ko) * | 2015-09-29 | 2018-05-24 | 애퍼런트 파마슈티컬스 인크. | 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제 |
| MA43821A (fr) * | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| MA44489A (fr) * | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | Pyrimidines et variants de celles-ci, et leurs utilisations |
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
-
2020
- 2020-04-29 EP EP20799419.5A patent/EP3960179B1/en active Active
- 2020-04-29 JP JP2021564189A patent/JP7665529B2/ja active Active
- 2020-04-29 SG SG11202111877TA patent/SG11202111877TA/en unknown
- 2020-04-29 WO PCT/CN2020/087686 patent/WO2020221274A1/zh not_active Ceased
- 2020-04-29 CN CN202080032489.4A patent/CN114007619B/zh active Active
- 2020-04-29 BR BR112021021600A patent/BR112021021600A2/pt unknown
- 2020-04-29 US US17/607,438 patent/US20220211703A1/en active Pending
- 2020-04-29 MX MX2021013338A patent/MX2021013338A/es unknown
- 2020-04-29 AU AU2020265327A patent/AU2020265327B2/en active Active
- 2020-04-29 KR KR1020217038551A patent/KR102935436B1/ko active Active
- 2020-04-30 TW TW109114696A patent/TWI736243B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7665529B2 (ja) | 2025-04-21 |
| EP3960179A4 (en) | 2023-01-25 |
| US20220211703A1 (en) | 2022-07-07 |
| CN114007619A (zh) | 2022-02-01 |
| SG11202111877TA (en) | 2021-11-29 |
| TW202106302A (zh) | 2021-02-16 |
| CA3138780A1 (en) | 2020-11-05 |
| KR102935436B1 (ko) | 2026-03-05 |
| EP3960179A1 (en) | 2022-03-02 |
| EP3960179B1 (en) | 2026-03-18 |
| CN114007619B (zh) | 2024-08-06 |
| MX2021013338A (es) | 2022-01-24 |
| TWI736243B (zh) | 2021-08-11 |
| AU2020265327B2 (en) | 2025-09-11 |
| AU2020265327A1 (en) | 2021-12-16 |
| KR20220007620A (ko) | 2022-01-18 |
| JP2022530890A (ja) | 2022-07-04 |
| WO2020221274A1 (zh) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| SA518391836B1 (ar) | تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه | |
| CL2023001369A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112021017354A2 (pt) | Método para o tratamento de doença hepática adiposa e/ou esteatoepatite | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| BR112013028430A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto | |
| EA201690386A1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
| MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
| BR112021026214A2 (pt) | Método para tratamento de fibrose pulmonar idiopática | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| BR112015020600A2 (pt) | composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição | |
| PH12022551523A1 (en) | Cyclic compounds and methods of using same | |
| BR112016015235A2 (pt) | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento | |
| MY196788A (en) | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| PH12018500653B1 (en) | Salts and solid forms of monobactam antibiotic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |